PAVmed Inc.
No SEC Form 4 filings for $PAVM in the last 30 days.
See all $PAVM insider activity →PAVmed Inc. (PAVM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards
PAVmed Inc. (NASDAQ: PAVM) reported Q2 2026 results for the quarter ended June 30, 2026 and provided business updates across subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health, and Octeris. Lucid recognized $1.5M EsoGuard revenue and processed 2,770 tests, and secured first lab benefit manager coverage. PAVmed cash was $3.8M; GAAP net loss was $5.5M ($0.87/share).
PAVmed Inc. (PAVM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001624326 0001624326 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report
Over the past 7 days, alphai's AI scored 2 news stories mentioning PAVM (PAVmed Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent PAVM coverage spans financial news, earnings and corporate actions.
Near-term trading focus is likely on cash runway, ongoing FDA-path milestones, and whether the quarter’s progress reduces perceived regulatory and commercialization risk.
Near-term trading focus is likely on liquidity (cash burn runway) and progress toward FDA milestones and coverage expansion within subsidiaries.
Governance/compensation updates via director re-election and ESPP share-plan expansion; likely low immediate impact on fundamentals or near-term valuation.
PAVmed Inc. is expected to report a significant loss of 70 cents per share, indicating potential short-term negative sentiment.
The registration of approximately 9.23 million shares for resale by existing stockholders indicates potential for increased share liquidity and possible downward pressure on the stock price if resales occur actively. The company will not receive proceeds from these resales, but warrants could generate up to $30 million if exercised, which may be dilutive in the future.
alphai scores every news story that mentions PAVM with an AI model for sentiment and relevance, and aggregates insider trades from PAVmed Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PAVmed Inc. (PAVM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards
6 min readPAVmed Inc. (NASDAQ: PAVM) reported Q2 2026 results for the quarter ended June 30, 2026 and provided business updates across subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health, and Octeris. Lucid recognized $1.5M EsoGuard revenue and processed 2,770 tests, and secured first lab benefit manager coverage. PAVmed cash was $3.8M; GAAP net loss was $5.5M ($0.87/share).
7 min readPAVmed Inc. (PAVM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001624326 0001624326 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report
3 min readPAVmed Inc. (PAVM) is projected to report a loss of 70 cents per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article is very brief and provides no additional details.
1 min readPAVmed Inc. has registered 9,230,786 shares of common stock for resale by existing stockholders, including shares issued from the conversion of Series D preferred stock and shares issuable from related warrants. The company will not receive proceeds from these resales, but could receive up to $30 million if the warrants are exercised. This registration allows selling stockholders to sell shares on public markets, subject to various market conditions and limitations.
2 min readScott V. Dols has reported a beneficial ownership of 346,155 shares, representing a 5.4% stake in PAVmed Inc. (NASDAQ: PAVM). This disclosure was made via a Schedule 13G SEC filing, based on 6,383,089 shares outstanding as of March 27, 2026. Dols holds sole voting and dispositive power over these shares, which include 230,770 shares held in a trust where he serves as trustee.
2 min readPAVmed Inc. (PAVM) released its 2025 Q4 earnings, reporting an EPS of -$1.05, beating estimates by $3.45. The company's revenue reached $52.00K, a 420.00% year-over-year increase, also surpassing expectations by $52.00K. The article highlights the earnings call presentation slides published by PAVmed Inc.
3 min readPAVmed reported a Q4 2025 non-GAAP EPS of -$1.05 and increased its cash position to $1.5 million. The company announced a 1-for-30 reverse stock split to boost share price and managed operating expenses of $6.9 million including stock-based compensation. Analysts have a "Moderate Buy" rating for PAVM with forecasted price increases.
3 min readPAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2 min readPAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min read
